Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., a prominent player in the health care sector, has been making significant strides in the pharmaceutical industry. Based in Zhangzhou, China, the company is renowned for its specialization in the manufacturing and marketing of traditional Chinese medications. Among its diverse product range, Pientzehuang, Pientzehuang capsules, Pientzehuang lozenges, and cough syrups stand out as flagship offerings. These products underscore the company’s commitment to integrating traditional Chinese medicine with modern pharmaceutical practices.
As of November 20, 2025, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. was trading at a close price of 176.2 CNY on the Shanghai Stock Exchange. This figure reflects a notable performance within the market, especially when considering the company’s 52-week high of 237.66 CNY on November 27, 2024, and its 52-week low of 174.51 CNY on November 5, 2025. The company’s market capitalization stands at an impressive 106,300,000,000 CNY, highlighting its substantial presence and influence in the pharmaceutical industry.
The company’s financial metrics, such as a price-to-earnings ratio of 43.99, indicate a robust valuation, reflecting investor confidence in its growth prospects and operational efficiency. Since its Initial Public Offering (IPO) on May 30, 2003, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. has demonstrated consistent growth and resilience, adapting to market dynamics while maintaining its core focus on traditional Chinese medicine.
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. continues to leverage its expertise in traditional Chinese medicine to expand its product portfolio and enhance its market reach. The company’s strategic initiatives are aimed at strengthening its position in the health care sector, both domestically and internationally. For more information, stakeholders and interested parties can visit the company’s official website at www.zzpzh.com .
In summary, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. remains a key player in the pharmaceutical industry, with a strong emphasis on traditional Chinese medications. Its financial performance and strategic direction suggest a promising future, as it continues to innovate and expand its influence in the global health care market.
